Novartis AG Total Assets
Novartis AG total assets. Based on the latest financial reports, Novartis AG (NOVN) holds total assets worth CHF118.89 Billion CHF (≈ $150.31 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see NOVN market cap for the company's overall valuation and market capitalisation.
Total Assets of Novartis AG (1998–2025)
Total assets of Novartis AG from 1998 to 2025. This chart illustrates how Novartis AG's total assets have evolved over time, based on quarterly financial data. See today's stock price for Novartis AG for real-time trading data and today's change.
Novartis AG - Asset Composition Analysis
Novartis AG Total Assets Breakdown (December 2025)
Novartis AG total assets breakdown as of December 2025. Novartis AG's total assets of CHF118.89 Billion consist of 26.4% current assets and 73.6% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF8.86 Billion | 9.9% |
| Accounts Receivable | CHF10.93 Billion | 9.5% |
| Inventory | CHF6.26 Billion | 5.4% |
| Property, Plant & Equipment | CHF12.35 Billion | 10.7% |
| Intangible Assets | CHF29.39 Billion | 25.5% |
| Goodwill | CHF25.55 Billion | 22.1% |
Asset Composition Trend (1998–2025)
This chart illustrates how Novartis AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Novartis AG (NOVN) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Novartis AG's current assets represent 26.4% of total assets in 2025, a decrease from 53.3% in 1998.
- Cash Position: Cash and equivalents constituted 9.9% of total assets in 2025, down from 12.4% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 10.0% in 1998.
- Asset Diversification: The largest asset category is intangible assets at 25.5% of total assets.
Novartis AG Competitors by Total Assets
Key competitors of Novartis AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
AstraZeneca PLC
LSE:AZN
|
UK | GBX116.43 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
China | CN¥2.55 Billion |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.18 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
Novartis AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.85 | 0.79 | 0.80 |
| Quick Ratio | 0.65 | 0.61 | 0.56 |
| Cash Ratio | 0.00 | 0.22 | 0.17 |
| Working Capital | CHF-4.78 Billion | CHF-6.51 Billion | CHF-5.83 Billion |
Novartis AG - Advanced Valuation Insights
This section examines the relationship between Novartis AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.21 |
| Latest Market Cap to Assets Ratio | 1.87 |
| Asset Growth Rate (YoY) | 13.0% |
| Total Assets | CHF115.49 Billion |
| Market Capitalization | $216.30 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Novartis AG's assets above their book value (1.87x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Novartis AG's assets grew by 13.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Novartis AG (1998–2025)
The table below shows the annual total assets of Novartis AG from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CHF115.49 Billion ≈ $146.01 Billion |
+12.96% |
| 2024-12-31 | CHF102.25 Billion ≈ $129.27 Billion |
+2.30% |
| 2023-12-31 | CHF99.94 Billion ≈ $126.36 Billion |
-14.91% |
| 2022-12-31 | CHF117.45 Billion ≈ $148.49 Billion |
-10.88% |
| 2021-12-31 | CHF131.79 Billion ≈ $166.62 Billion |
+3.14% |
| 2020-12-31 | CHF127.78 Billion ≈ $161.55 Billion |
+7.95% |
| 2019-12-31 | CHF118.37 Billion ≈ $149.65 Billion |
-18.68% |
| 2018-12-31 | CHF145.56 Billion ≈ $184.03 Billion |
+9.38% |
| 2017-12-31 | CHF133.08 Billion ≈ $168.25 Billion |
+2.27% |
| 2016-12-31 | CHF130.12 Billion ≈ $164.51 Billion |
-1.09% |
| 2015-12-31 | CHF131.56 Billion ≈ $166.32 Billion |
+4.92% |
| 2014-12-31 | CHF125.39 Billion ≈ $158.52 Billion |
-0.69% |
| 2013-12-31 | CHF126.25 Billion ≈ $159.62 Billion |
+1.66% |
| 2012-12-31 | CHF124.19 Billion ≈ $157.01 Billion |
+5.70% |
| 2011-12-31 | CHF117.50 Billion ≈ $148.55 Billion |
-4.72% |
| 2010-12-31 | CHF123.32 Billion ≈ $155.91 Billion |
+29.12% |
| 2009-12-31 | CHF95.50 Billion ≈ $120.74 Billion |
+21.97% |
| 2008-12-31 | CHF78.30 Billion ≈ $98.99 Billion |
+3.77% |
| 2007-12-31 | CHF75.45 Billion ≈ $95.39 Billion |
+10.95% |
| 2006-12-31 | CHF68.01 Billion ≈ $85.98 Billion |
+17.80% |
| 2005-12-31 | CHF57.73 Billion ≈ $72.99 Billion |
+9.99% |
| 2004-12-31 | CHF52.49 Billion ≈ $66.36 Billion |
+6.43% |
| 2003-12-31 | CHF49.32 Billion ≈ $62.35 Billion |
+9.53% |
| 2002-12-31 | CHF45.02 Billion ≈ $56.92 Billion |
+11.71% |
| 2001-12-31 | CHF40.30 Billion ≈ $50.96 Billion |
+11.78% |
| 2000-12-31 | CHF36.06 Billion ≈ $45.59 Billion |
-12.36% |
| 1999-12-31 | CHF41.14 Billion ≈ $52.02 Billion |
+0.69% |
| 1998-12-31 | CHF40.86 Billion ≈ $51.66 Billion |
-- |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more